Toxicity of Aromatase Inhibitors

Seminars in Oncology

Volumn 33, Issue 6, 2006, Pages 688-695

  Pandya, Naimish ^a   Morris, Gloria J ^a  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; APOLIPOPROTEIN B; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CHOLESTEROL; EXEMESTANE; FADROZOLE; FORMESTANE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LETROZOLE; LIPID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TAMOXIFEN; TRIACYLGLYCEROL; VITAMIN D; ZOLEDRONIC ACID;

ADJUVANT THERAPY; ARTHRALGIA; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BONE DENSITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CARCINOMA IN SITU; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; FRACTURE; HUMAN; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MUSCULOSKELETAL SYSTEM; MYALGIA; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; SIDE EFFECT; TASK PERFORMANCE; TOXICOLOGY; TRIACYLGLYCEROL BLOOD LEVEL; VERBAL MEMORY; WORD RECOGNITION;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; ARTHRALGIA; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COGNITION; FEMALE; HUMANS; LIPID METABOLISM; MUSCULOSKELETAL SYSTEM; OSTEOPOROSIS; QUALITY OF LIFE;

EID: 34848832272     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2006.08.011     Document Type: Article

References (63)

1. Jemal A., Siegel R., Ward E., et al. Cancer Statistics, 2006. CA Cancer J Clin 56 (2006) 106-130
2. National Cancer Institute: Cancer Surveillance Research. Fast Stats: Breast Cancer. Survival & Stage: Stage Distribution. Surveillance, Epidemiology, and End Results (SEER) program. http://seer.cancer.gov/faststats/
3. Theobald A.J. Management of advanced breast cancer with endocrine therapy: the role of the primary healthcare team. Int J Clin Pract 54 (2000) 665-669
4. Buzdar A.U., Robertson J.F.R., Eiermann W., et al. An overview of the pharmacology and pharmockinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. Cancer 95 (2002) 2006-2016
5. Buzdar A.U., Douma J., Davidson N., et al. Phase III, multicenter, double-blind randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 19 (2001) 3357-3366
6. Bonneterre J., Thurlimann B., Robertson J.F., et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 18 (2000) 3748-3757
7. Mouridesen H., Gershanovich M., Sun Y., et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19 (2001) 2596-2606
8. Nabholtz J.M., Buzdar A., Pollak M., et al., Arimidex Study Group. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial. J Clin Oncol 18 (2000) 3758-3767
9. Paridaens R., Therasse P., Dirix L., et al. First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients-A randomized phase III trial of the EORTC Breast Group (2004) 2004 ASCO Annual Meeting Proceedings (post-meeting edition), 23, (abstr 515)
10. Gradishar W.J. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women. Oncology 69 (2005) 1-9
11. Beatson G.T. On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment with illustrative cases. Lancet 2 (1896) 104-107
12. Carpenter R., and Miller W.R. Role of aromatase inhibitors in breast cancer. Br J Cancer 93 suppl 1 (2005) S1-S5
13. Simpson E.R., and Davis S.R. Minireview: Aromatase and the regulation of estrogen biosynthesis-Some new perspectives. Endocrinology 142 (2001) 4589-4594
14. Miller W.R., and Dixon J.M. Local endocrine effects of aromatase inhibitors within the breast. J Steroid Biochem Mol Biol 79 (2001) 93-102
15. National Comprehensive Cancer Network. Breast Cancer: Clinical practice guidelines in oncology-v.1.200 (2005). http://www.nccn.org/physician_gls/f_guidelines.html http://www.nccn.org/physician_gls/f_guidelines.html
16. Eisen A., Pritchard K., Johnston M., et al., Breast Cancer Disease Site Group. The role of aromatase inhibitors in the treatment of postmenopausal women with metastatic breast cancer. Cancer Care Ontario (2002) Practice Guideline Report No.1-5
17. Blamey R.W. Guidelines on endocrine therapy of breast cancer. Eur J Cancer 38 (2002) 615-634
18. Lester J.E., Dodwell D., Horsman J.M., et al. Current management of treatment-induced bone loss in women with breast cancer treated in the United Kingdom. Br J Cancer 94 (2006) 30-35
19. Lester J., and Coleman R. Bone loss and aromatase inhibitors. Br J Cancer 93 suppl 1 (2005) S16-S22
20. Shapiro C., Manola J., and Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 19 (2001) 3306-3311
21. Vehmanen L., Saarto T., Elomaa I., et al. Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of clodronate treatment. Eur J Cancer 37 (2001) 2373-2378
22. Wheeler D.L., Vander Greind R.A., Wronski T.J., et al. The short and long-term effects of methotrexate on the rat skeleton. Bone 16 (1995) 215-221
23. Greep N.C., Giuliano A.E., Hansen N.M., et al. The effects of adjuvant chemotherapy on bone density in postmenopausal women with early breast cancer. Am J Med 11 (2003) 653-659
24. Powles T.J., Hickish T., Kanis J.A., et al. Effect of tamoxifen on bone mineral density measured by dual energy x-ray absorpimetry in health premenopausal and postmenopausal women. J Clin Oncol 14 (1996) 78-84
25. Leather A.T., Studd J.W., Watson N.R., et al. The prevention of bone loss in young women treated with GnRH analogues with 'add back' estrogen therapy. Obstet Gynecol 81 (1993) 104-107
26. Hashimoto K., Nozaki M., Inoue Y., et al. The chronological change of vertebral bone loss following oophroectomy using dual energy x-ray absorptiometry: The correlation with specific markers of bone metabolism. Maturitas 22 (1995) 185-192
27. Eastell R., Hannon R.A., Cuzick J., et al. Effect of anastrozole on bone density and bone turnover: results of the 'Arimidex' (anastrozole), Tamoxifen Alone or in Combination (ATAC) trial bone sub-protocol (2002) 24th Annual Meeting American Society for Bone and Mineral Research, San Antonio, TX, (abstr 1170)
28. Goss P.E., Ingle J.N., Martino S., et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349 (2003) 1793-1802
29. Coombes R.C., Hall E., Gibson L.J., et al., Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350 (2004) 1081-1092
30. Lonning P.E., Geisler J., Krag L.E., et al. Effect of exemestane on bone: A randomized placebo controlled study in postmenopausal women with early breast cancer at low risk. J Clin Onco 22 14S (2004) 518 (abstr)
31. Love R.R., Mazess R.B., Barden H.S., et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326 (1992) 852-856
32. Winer E.P., Hudis C., Burstein H.J., et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004. J Clin Oncol 23 (2005) 619-629
33. Lonning P.E., Jurgen G., Krag L.E., et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 23 (2005) 5126-5137
34. Looker A.C., Bauer D.C., Chestnut C.H., et al. Clinical use of biochemical markers of bone remodeling: Current status and future directions. Osteoporos Int 11 (2000) 467-480
35. Johannessen D.C., Engan T., diSalle E., et al. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients. A phase I study. Clin Cancer Res 3 (1997) 1101-1108
36. ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 (2005) 60-62
37. Eastell R., Hannon R.A., Cuzick J., et al. Effect of anastrozole on bone density and bone turnover: Results of the 'Arimidex' (anastrozole), Tamoxifen Alone or in Combination (ATAC) trial bone sub-protocol (2002) 24th Annual Meeting American Society for Bone and Mineral Research, San Antonio, TX, (abstr 1170)
38. Boccardo F., Rubagotti A., Puntoni M., et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: Preliminary results of the Italian tamoxifen anastrozole trial. J Clin Oncol 23 (2005) 5138-5147
39. Goss P.E., Ingle J.N., Martino S., et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97 (2005) 1262-1271
40. Perez E.A., Josse R.G., Pritchard K.I., et al. Effect of letrozole versus placebo on bone mineral density in women completing ≥5 years of adjuvant tamoxifen: NCIC CTG MA.17b (2004) 27th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, (abstr 404)
41. Goss P., Thompsen T., and Banke-Bochita J. A randomized, placebo-controlled, explorative study to investigate the effect of low estrogen plasma levels on markers of bone turnover in healthy postmenopausal women during the 12-week treatment with exemestane or letrozole. Breast Cancer Res Treat 76 (2002) S76 (suppl 1, abstr 267)
42. The Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353 (2005) 2747-2757
43. Brufsky A., Harker G., Beck T., et al., Z-FAST Study Group. Zoledronic acid (ZA) for prevention of cancer treatment-induced bone loss (CTIBL) in postmenopausal women with early breast cancer receiving adjuvant Letrozole: Preliminary results of the Z-FAST trial (2004) 27th Annual San Antonio Breast Cancer Symposium, (abstr 1114)
44. Brufsky A., Harker W., Beck J., et al., Z-FAST Study Group. Zoledronic acid (ZA) effectively inhibits cancer treatment-induced bone loss (CTIBL) in postmenopausal women with early breast cancer receiving adjuvant letrozole: 12 mos BMD results of the Z-FAST trial. 2005 ASCO Annual Meeting Proceedings. J Clin Oncol 23 (2005) 533 (suppl, abstr)
45. Hillner B.E., Ingle J.N., Chlebowski R.T., et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21 (2003) 4042-4057
46. Miller-Bass K., Newschaffer C.J., Klag M.J., et al. Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med 154 (1994) 2349-2355
47. La Rosa J.C. Triglycerides and coronary risk in women and the elderly. Arch Intern Med 157 (1997) 961-968
48. Danesh J., Collins R., and Peto R. Lipoprotein (a) and coronary heart disease: Meta-analysis of prospective studies. Circulation 102 (2000) 1082-1085
49. deAloysio D., Gambacciani M., Meschia M., et al., The Icarus Study Group. The effect of menopause on blood lipid and lipoprotein levels. Atherosclerosis 147 (1999) 147-153
50. Levi F., Randimbison L., Te V.C., et al. Long-term mortality of women with a diagnosis of breast cancer. Oncology 63 (2002) 266-269
51. Bundred N.J. The effects of aromatase inhibitors on lipids and thrombosis. Br J Cancer 93 suppl 1 (2005) S23-S27
52. Atalay G., Dirix L., Biganzoli L., et al. The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: A companion study to EORTC trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients. Ann Oncol 15 (2004) 211-217
53. Markopoulos C., Polychronis A., Zobolas V., et al. The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: Preliminary results of the TEAM Greek sub-study. Breast Cancer Res Treat 93 (2005) 61-66
54. Hozumi Y., Saito T., Inoue K., et al. Effects of anastrozole on the lipid profile in postmenopausal breast cancer patients-A preliminary study (2004) Fourth European Breast Cancer Conference, Hamburg, Germany, (abstr 300)
55. Felson D.T., and Cummings S.R. Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation. Arthritis Rheum 52 (2005) 2594-2598
56. Kidd B.L., Photiou A., and Inglis J.J. The role of inflammatory mediators on nociception and pain in arthritis. Novartis Found Symp 260 (2004) 122-133
57. Blomqvist A. Sex hormones and pain: A new role for brain aromatas?. J Comp Neurol 423 (2000) 549-551
58. Donnellan P.P., Douglas S.L., Cameron D.A., et al. Aromatase inhibitors and arthralgia. J Clin Oncol 19 (2001) 2767 (letter)
59. Stoffel-Wagner B. Neurosteroid metabolism in the human brain. Eur J Endocrinol 145 (2001) 669-679
60. McEwen B.S. Clinical review 108: The molecular and neuroanatomical basis for estrogen effects in the central nervous system. J Clin Endocrinol Metab 84 (1999) 1790-1797
61. Jenkins V.A., Schiling V., Fallowfield L.J., et al. Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition?. A pilot study. Psychooncology 13 (2004) 61-66
62. Jones J., Vukelja S., Cantrell J., et al. A planned comparison of menopausal symptoms during year 1 in patients receiving either exemestane or tamoxifen in a double-blind adjuvant hormonal study. Breast Cancer Res Treat 82 (2003) S31
63. Tralongo P., DiMari A., and Ferrau F. Cognitive impairment, aromatase inhibitors and age. J Clin Oncol 23 (2005) 4243